AstraZeneca Reports Strong Q2 Results

by webmaster

AstraZeneca, the Anglo-Swedish pharmaceutical giant, has announced its financial results for the second quarter of the year, surpassing market expectations and providing a positive outlook for the full year. The company’s shares saw a 3.7% increase following the announcement.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Impressive Revenue and Earnings Growth

AstraZeneca reported a significant rise in both revenue and earnings per share for Q2 2023. Core earnings per share increased by 25% to $2.15, outperforming the consensus estimate of $1.98 from 19 analysts. The total revenue for the quarter reached $11.42 billion, exceeding last year’s figure of $10.77 billion. This growth was supported by double-digit growth across all non-Covid-19 therapy areas.

Positive Outlook for 2023

AstraZeneca remains confident in its performance for the remainder of the year. The company has backed its guidance for 2023, projecting a low-to-mid single-digit increase in total revenue at constant exchange rates. Excluding Covid-19 medicines, total revenue is expected to grow by a low double-digit percentage. Additionally, core earnings per share are anticipated to increase by a high single-digit to low double-digit percentage.

Decline in Revenue from Covid-19 Medicines

While AstraZeneca experienced substantial growth in its overall revenue, it expects a significant decline in revenue from Covid-19 medicines, including its vaccine, for the upcoming year.

These results showcase AstraZeneca’s strong performance in the second quarter and instill confidence in its future prospects.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Related Articles

Leave a Comment

67 + = 69